Key result
Combined chemotherapy with ifosfamide and doxorubicin yielded a partial response in a 25-year-old woman with primary diaphragmatic malignant fibrous histiocytoma, though she died at 12 months.
Case Report (n=1)
Primary malignant fibrous histiocytoma of the diaphragm is an extremely rare event in young patients and can have a poor prognosis despite initial response to chemotherapy.
May offer transient control in rare diaphragmatic MFH; leaves open standardized therapy and prognosis data.
A malignant fibrous histiocytoma (MFH) is a major subset of soft tissue sarcomas, which occurs principally on the extremities or in the retroperitoneum, as well as on the head and neck of elderly patient. However, it is an extremely rare event when a MFH occurs primarily in the diaphragm of a young people. A 25-year-old woman visited our hospital complaining of right chest pain. The chest X-ray showed a diaphragmatic mass. An exploratory thoracotomic biopsy revealed a primary MFH of the diaphragm. The patient was treated with combined chemotherapy consisting of ifosfamide and doxorubicin. A partial response was seen after 6 cycles of chemotherapy. However, she died of brain metastasis 12 months after the diagnosis.
No takes yet. Share an insight, caveat, or question.
Shim et al. (2003) conducted a case report in Primary malignant fibrous histiocytoma of the diaphragm (n=1). Combined chemotherapy (ifosfamide and doxorubicin) was evaluated on Clinical response and survival. Combined chemotherapy with ifosfamide and doxorubicin yielded a partial response in a 25-year-old woman with primary diaphragmatic malignant fibrous histiocytoma, though she died at 12 months.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: